Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments
Abstract
Background: In multiple sclerosis (MS), accelerated aging of the immune system (immunosenescence) may be associated with disease onset or drive progression. DNA methylation (DNAm) is an epigenetic factor that varies among lymphocyte subtypes, and cell specific DNAm is associated with MS. DNAm varies across the lifespan and can be used to accurately estimate biological age acceleration which has been linked to a range of morbidities.
Objective: To test for cell specific epigenetic age acceleration (EAA) in people with MS.
Methods: This was a case-control, study of EAA using existing DNAm data from several independent, previously published studies. Data was included if .idat files from Illumina 450K or EPIC arrays were available for both an MS case and an age and sex matched control, from the same study. Multifactor statistical modelling was performed to assess the primary outcome of EAA. We explored the relationship of EAA and MS, including interaction terms to identify immune cell specific effects. Cell sorted DNA methylation data from three independent datasets was used to validate findings.
Results: We used whole blood DNA methylation data from 583 MS cases and 643 non-MS controls to calculate EAA using the GrimAge algorithm. The MS group exhibited an increased EAA compared to controls (∼9 mths, 95%CI: 3.6-14.4), P = 0.001). Statistical deconvolution showed that EAA is associated with MS in a B cell dependent manner (βint=1.7, 95%CI: 0.3-2.8), P = 0.002), irrespective of B cell proportions. Validation analysis using three independent datasets enriched for B cells, showed an EAA increase of 5.1yrs in MS compared to controls (95%CI: 2.8-7.4, P = 5.5×10-5). By comparison, there was no EAA difference in MS in a T cell enriched dataset. We found that EAA was attributed to the DNAm surrogates for Beta-2-microglobulin (difference = 47,546, 95%CI: 10,067-85,026; P = 7.2×10-5), and smoking pack years (difference = 8.1, 95%CI: 1.9-14.2, P = 0.002).
Conclusion: This study provides compelling evidence that B cells exhibit marked EAA in MS and supports the hypothesis that premature B cell immune senescence plays a role in MS. Future MS studies should focus on age-related molecular mechanisms in B cells.
- Received December 8, 2022.
- Accepted in final form April 20, 2023.
- Copyright © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Related Articles
- No related articles found.